Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Archives of Dermatological Research
Published in: Archives of Dermatological Research 5/2011

01-07-2011 | Original Paper

Neurofibromatosis type 1 (NF1) and pheochromocytoma: prevalence, clinical and cardiovascular aspects

Authors: Laura Zinnamosca, Luigi Petramala, Dario Cotesta, Cristiano Marinelli, Mauro Schina, Rosario Cianci, Sandra Giustini, Susanna Sciomer, Emanuela Anastasi, Stefano Calvieri, Giorgio De Toma, Claudio Letizia

Published in: Archives of Dermatological Research | Issue 5/2011

Login to get access

Abstract

The aim of the study was to evaluate the prevalence of pheochromocytoma (PHEO) in patients with neurofibromatosis type 1 (NF1), and to analyze the behavior of some anthropometric and cardiovascular parameters. In 48 consecutive NF1 patients, urinary metanephrines and vanillylmandelic acid excretion were assessed. The body mass index (BMI), waist circumference (WC), ambulatory blood pressure monitoring (ABPM), echocardiography and ultrasound carotid arterial wall evaluation were performed. In NF1 patients, 11 (29.3%) had arterial hypertension, 7 (14.6%) had a PHEO. Four (57%) NF1 patients with PHEO were symptomatic at the diagnosis. In PHEO-NF1 patients, we revealed a lower BMI and WC values with respect to NF1 patients without PHEO and normal subjects (NSs) (p < 0.05), respectively. The nocturnal non-dipping pattern at the ABPM was present in 40.4% of NF1 patients, and in particular this phenomenon was present in PHEO-NF1 patients (71.4%). Left ventricular mass index and intima media thickness were significantly higher in NF1 patients as compared to NS (p < 0.05), particularly in NF1-PHEO patients (p < 0.05). In conclusions, these findings revealed high prevalence of PHEO in NF1 patients and suggest that, in addition to blood pressure, humoral factors (increased sympathetic activity or neurofibromin), influence the pathogenesis of remodeling of cardiovascular system.
Literature
1.
Bausch B, Borozdin W, Mautner VF et al (2007) Germline NF1 mutational spectra and loss-of-heterozygosity analyses in patients with pheochromocytoma and neurofibromatosis type 1. J Clin Endocrinol Metab 92(7):2784–2792PubMedCrossRef
2.
Bravo EL, Tagle R (2003) Pheochromocytoma: state-of-the-art and future prospects. Endocr Rev 24:539–553PubMedCrossRef
3.
Ceruti M, Petramala L, Cotesta D et al (2006) Ambulatory blood pressure monitoring in secondary arterial hypertension due to adrenal diseases. J Clin Hypertens 8:642–648CrossRef
4.
Cichowski K, Jacks T (2001) NF1 tumor suppressor gene function: narrowing the GAP. Cell 104:593–604PubMedCrossRef
5.
Cotesta D, Erlic Z, Petramala L et al (2008) Coincidence of neurofibromatosis Type 1 and multiple endocrine neoplasia type 2. Endocrinologist 18:277–281CrossRef
6.
Denolle T, Chatellier G, Julien J et al (1993) Left ventricular mass and geometry before and after etiologic treatment in renovascular hypertension, aldosterone-producing adenoma, and pheochromocytoma. Am J Hypertens 6:907–913PubMed
7.
Ferner RE, Huson SM, Thomas N et al (2007) Guidelines for the diagnosis and management of individuals with neurofibromatosis 1. J Med Genet 44(2):81–88PubMedCrossRef
8.
9.
10.
Goldberg NS, Roenigk RK (1996) Neurofibromatosis, tuberous sclerosis, and other neurocutaneous discorde. In: Wintronb BU (ed) Cutaneous medicine and surgery: an interpretated program in dermatology. WB Saunders, Philadelpfia, pp 1729–1741
11.
Goldstein DS, Eisenhofer G, Flynn JA et al (2004) Diagnosis and localization of pheochromocytoma. Hypertension 43:907–910PubMedCrossRef
12.
Gutmann DH, Aylsworth A, Carey JC et al (1997) The diagnostic evaluation and multidisciplinary management of neurofibromatosis 1 and neurofibromatosis 2. JAMA 278:51–57PubMedCrossRef
13.
Hansen TW, Jeppesen J, Rasmussen S, Ibsen H, Torp-Pedersen C (2006) Ambulatory blood pressure monitoring and risk of cardiovascular disease: a population based study. Am J Hypertens 19(3):243–250PubMedCrossRef
14.
Heineke J, Molkentin JD (2006) Regulation of cardiac hypertrophy by intracellular signalling pathways. Nat Rev Mol Cell Biol 7:589–600PubMedCrossRef
15.
Heniford BT, Arca MJ, Walsh RM, Gill IS (1999) Laparoscopic adrenalectomy for cancer. Semin Surg Oncol 16(4):293–306PubMedCrossRef
16.
Huson SM, Compston DA, Clark P et al (1989) A genetic study of von Recklinghausen neurofibromatosis in south east Wales. I. Prevalence, fitness, mutation rate, and effect of parental transmission on severity. J Med Genet 26:704–711PubMedCrossRef
17.
Ito Y, Fujimoto Y, Obara T (1992) The role of epinephrine, norepinephrine, and dopamine in blood pressure disturbances in patients with pheochromocytoma. World J Surg 16:759–763PubMedCrossRef
18.
Jenne DE, Tinschert S, Reimann H et al (2001) Molecular characterization and gene content of breakpoint boundaries in patients with neurofibromatosis type 1 with 17q11.2 microdeletions. Am J Hum Genet 69:516–527PubMedCrossRef
19.
Kurpad AV, Khan K, Calder AG, Elia M (1994) Muscle and whole body metabolism after norepinephrine. Am J Physiol 266:E877–E884PubMed
20.
La Batide-Alanore A, Chatellier G, Plouin PF (2003) Diabetes as a marker of pheochromocytoma in hypertensive patients. J Hypertension 21:1703–1707CrossRef
21.
Lakkis MM, Epstein JA (1998) Neurofibromin modulation of Ras activity is required for normal endocardial-mesenchymal transformation in the developing heart. Development 125:4359–4367PubMed
22.
23.
Mancia G, Ferrari A, Gregorini L et al (1983) Blood pressure and heart rate variabilities in normotensive and hypertensive human beings. Circ Res 53:96–104PubMed
24.
Mannelli M, Ianni L, Cilotti A et al (1999) Pheochromocytoma in Italy: a multicentric retrospective study. Eur J Endocrinol 141:619–624PubMedCrossRef
25.
Millar-Craig MW, Bishop CN, Raftery EB (1978) Circadian variation of blood-pressure. Lancet 1:795–797PubMedCrossRef
26.
Norton KK, Xu J, Gutmann DH (1995) Expression of the neurofibromatosis I gene product, neurofibromin, in blood vessel endothelial cells and smooth muscle. Neurobiol Dis 2:13–21PubMedCrossRef
27.
28.
Pacak K, Linehan WM, Eisenhofer G et al (2001) Recent advances in genetics, diagnosis, localization, and treatment of pheochromocytoma. Ann Intern Med 134:315–329PubMed
29.
Palatini P, Penzo M, Racioppa A et al (1992) Clinical relevance of nighttime blood pressure and of daytime blood pressure variability. Arch Intern Med 152:1855–1860PubMedCrossRef
30.
Rizzoni D, Muiesan ML, Porteri E et al (1998) Relations between cardiac and vascular structure in patients with primary and secondary hypertension. J Am Coll Cardiol 32:985–992PubMedCrossRef
31.
Routledge F, McFetridge-Durdle J (2007) Non-dipping blood pressure patterns among individuals with essential hypertension: a review of the literature. Eur J Cardiovasc Nurs 6:9–26PubMedCrossRef
32.
Shub C, Cueto-Garcia L, Sheps SG et al (1986) Echocardiographic findings in pheochromocytoma. Am J Cardiol 57:971–975PubMedCrossRef
33.
Tedesco MA, Di Salvo G, Natale F, Pergola V, Calabrese E, Grassia C, Ratti G, Iarussi D, Iacono A, Calabrò R, Lama G (2002) The heart in neurofibromatosis type 1: an echocardiographic study. Heart J. 143:883–888CrossRef
34.
Walther MM, Herring J, Enquist E et al (1999) von Recklinghausen’s disease and pheochromocytomas. J Urol 162:1582–1586PubMedCrossRef
35.
Xu J, Ismat FA, Wang T et al (2009) Cardiomyocyte-specific loss of neurofibromin promotes cardiac hypertrophy and dysfunction. Circ Res 105:304–311PubMedCrossRef
Metadata
Title
Neurofibromatosis type 1 (NF1) and pheochromocytoma: prevalence, clinical and cardiovascular aspects
Authors
Laura Zinnamosca
Luigi Petramala
Dario Cotesta
Cristiano Marinelli
Mauro Schina
Rosario Cianci
Sandra Giustini
Susanna Sciomer
Emanuela Anastasi
Stefano Calvieri
Giorgio De Toma
Claudio Letizia
Publication date
01-07-2011
Publisher
Springer-Verlag
Published in
Archives of Dermatological Research / Issue 5/2011
Print ISSN: 0340-3696
Electronic ISSN: 1432-069X
DOI
https://doi.org/10.1007/s00403-010-1090-z

Other articles of this Issue 5/2011

Archives of Dermatological Research 5/2011 Go to the issue

Short Communication

Plasma cluster ions decrease the antigenicity of mite allergens and suppress atopic dermatitis in NC/Nga mice

Original Paper

ACE inhibitors can induce circulating antibodies directed to antigens of the superficial epidermal cells

Original Paper

Peoniflorin suppresses tumor necrosis factor-α induced chemokine production in human dermal microvascular endothelial cells by blocking nuclear factor-κB and ERK pathway

Short Communication

Seven novel mutations in the ATP2A2 gene of Austrian patients with Darier’s disease

Original Paper

Tea tree oil attenuates experimental contact dermatitis

Original Paper

Impairment of human keratinocyte mobility and proliferation by advanced glycation end products-modified BSA